Elicio Therapeutics' Phase 2 of ELI-002 7P in adjuvant pancreatic cancer misses primary endpoint

 

Elicio Therapeutics' Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant pancreatic cancer misses primary endpoint, Phase 3 to focus on R0 subgroup

• Phase 2 AMPLIFY-7P study in adjuvant pancreatic cancer did not meet primary disease-free survival endpoint in intent-to-treat population.
• Post-hoc analysis showed clinical benefit for R0-resected patients, supporting a refined Phase 3 development strategy focused on this subgroup.

https://finviz.com/stock?t=ELTX&p=d